Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease

Brain Research Bulletin

Volumn 87, Issue 6, 2012, Pages 571-578

  Lerner, Renata P ^a   Trejo Martinez, Luz del Carmen G ^a   Zhu, Chunni ^a   Chesselet, Marie Françoise ^a   Hickey, Miriam A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Corpus callosum; Cortex; Golgi stain; Huntingtin; Stereology; Volume

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; CAG REPEAT; CELL STRUCTURE; CONTROLLED STUDY; CORPUS CALLOSUM; DENDRITE; EXON; FEMALE; HOMOZYGOTE; HUNTINGTON CHOREA; MALE; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; SPINE; STEREOLOGY; STRIATAL ATROPHY; WILD TYPE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ATROPHY; BRAIN; CELL COUNT; CORPUS STRIATUM; DENDRITES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; SEX FACTORS; SILVER STAINING; TRINUCLEOTIDE REPEAT EXPANSION; TYROSINE 3-MONOOXYGENASE;

EID: 84859158535     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.01.012     Document Type: Article

References (51)

1. 2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996, 119:2085-2095.
2. Aylward E.H. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res. Bull. 2007, 72:152-158.
3. Aylward E.H., Nopoulos P.C., Ross C.A., Langbehn D.R., Pierson R.K., Mills J.A., Johnson H.J., Magnotta V.A., Juhl A.R., Paulsen J.S. Longitudinal change in regional brain volumes in prodromal Huntington disease. J. Neurol. Neurosurg. Psychiatry 2011, 82:405-410.
4. Azdad K., Chavez M., Don Bischop P., Wetzelaer P., Marescau B., De Deyn P.P., Gall D., Schiffmann S.N. Homeostatic plasticity of striatal neurons intrinsic excitability following dopamine depletion. PLoS One 2009, 4:e6908.
5. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., Greengard P. Severe deficiencies in dopamine signalling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:6809-6814.
6. Chopra V., Fox J.H., Lieberman G., Dorsey K., Matson W., Waldmeier P., Housman D.E., Kazantsev A., Young A.B., Hersch S. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16685-16689.
7. Cummings D.M., Cepeda C., Levine M.S. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro 2010, 2:e00036.
8. Deutch A.Y., Colbran R.J., Winder D.J. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat. Disord. 2007, 13(Suppl. 3):S251-S258.
9. Ferrante R.J., Kowall N.W., Richardson E.P. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 1991, 11:3877-3887.
10. Graveland G.A., Williams R.S., DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985, 227:770-773.
11. Gray M., Shirasaki D.I., Cepeda C., Andre V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
12. Gu X., Andre V.M., Cepeda C., Li S.H., Li X.J., Levine M.S., Yang X.W. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol. Neurodegener. 2007, 2:8.
13. Gu X., Li C., Wei W., Lo V., Gong S., Li S.H., Iwasato T., Itohara S., Li X.J., Mody I., Heintz N., Yang X.W. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005, 46:433-444.
14. Hickey M.A., Franich N.R., Medvedeva V., Chesselet M.F. Mouse models of mental illness and neurological disease: Huntington's disease. The Mouse Nervous System 2012, 752-765. Elsevier, London. C. Watson, G. Paxinos, L. Puelles (Eds.).
15. Hickey M.A., Kosmalska A., Enayati J., Cohen R., Zeitlin S., Levine M.S., Chesselet M.F. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 2008, 157:280-295.
16. Hickey M.A., Reynolds G.P., Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 2002, 81:46-59.
17. Hickey M.A., Zhu C., Medvedeva V., Franich N.R., Levine M.S., Chesselet M.-F. Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease. Mol Cell Neurosci 2012, 49:149-157.
18. Ho Kim S., Thomas C.A., Andre V.M., Cummings D.M., Cepeda C., Levine M.S., Ehrlich M.E. Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro 2011, 3.
19. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
20. Ingham C.A., Hood S.H., Arbuthnott G.W. Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res. 1989, 503:334-338.
21. Ingham C.A., Hood S.H., Taggart P., Arbuthnott G.W. Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway. J. Neurosci. 1998, 18:4732-4743.
22. Irwin S.A., Idupulapati M., Gilbert M.E., Harris J.B., Chakravarti A.B., Rogers E.J., Crisostomo R.A., Larsen B.P., Mehta A., Alcantara C.J., Patel B., Swain R.A., Weiler I.J., Oostra B.A., Greenough W.T. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. Am. J. Med. Genet. 2002, 111:140-146.
23. Johnson M.A., Rajan V., Miller C.E., Wightman R.M. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J. Neurochem. 2006, 97:737-746.
24. Joshi P.R., Wu N.P., Andre V.M., Cummings D.M., Cepeda C., Joyce J.A., Carroll J.B., Leavitt B.R., Hayden M.R., Levine M.S., Bamford N.S. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 2009, 29:2414-2427.
25. Kim S.H., Thomas C.A., Andre V.M., Cummings D.M., Cepeda C., Levine M.S., Ehrlich M.E. Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro 2011, 3:e00060.
26. Kish S.J., Shannak K., Hornykiewicz O. Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Ann. Neurol. 1987, 22:386-389.
27. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 2001, 86:2667-2677.
28. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 2001, 21:9112-9123.
29. Lundin A., Dietrichs E., Haghighi S., Goller M.L., Heiberg A., Loutfi G., Widner H., Wiktorin K., Wiklund L., Svenningsson A., Sonesson C., Waters N., Waters S., Tedroff J. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin. Neuropharmacol. 2010, 33:260-264.
30. McGeer P.L., McGeer E.G. Neurotransmitters and their receptors in the basal ganglia. Adv. Neurol. 1993, 60:93-101.
31. Melamed E., Hefti F., Bird E. Huntington chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: studies in postmortem tissues and in rats with kainic acid lesions. Neurology 1982, 32:640-644.
32. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 2003, 465:11-26.
33. Neely M.D., Schmidt D.E., Deutch A.Y. Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons. Neuroscience 2007, 149:457-464.
34. Paulsen J.S., Langbehn D.R., Stout J.C., Aylward E., Ross C.A., Nance M., Guttman M., Johnson S., MacDonald M., Beglinger L.J., Duff K., Kayson E., Biglan K., Shoulson I., Oakes D., Hayden M. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 2008, 79:874-880.
35. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego.
36. Phan J., Hickey M.A., Zhang P., Chesselet M.F., Reue K. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet. 2009, 18:1006-1016.
37. Reisine T.D., Fields J.Z., Bird E.D., Spokes E., Yamamura H.I. Characterization of brain dopaminergic receptors in Huntington's disease. Commun. Psychopharmacol. 1978, 2:79-84.
38. Reisine T.D., Fields J.Z., Stern L.Z., Johnson P.C., Bird E.D., Yamamura H.I. Alterations in dopaminergic receptors in Huntington's disease. Life Sci. 1977, 21:1123-1128.
39. Restivo L., Ferrari F., Passino E., Sgobio C., Bock J., Oostra B.A., Bagni C., Ammassari-Teule M. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11557-11562.
40. Rosas H.D., Hevelone N.D., Zaleta A.K., Greve D.N., Salat D.H., Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005, 65:745-747.
41. Rosas H.D., Lee S.Y., Bender A.C., Zaleta A.K., Vangel M., Yu P., Fischl B., Pappu V., Onorato C., Cha J.H., Salat D.H., Hersch S.M. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical disconnection. Neuroimage 2010, 49:2995-3004.
42. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., van der Kouwe A., Jenkins B.G., Dale A.M., Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58:695-701.
43. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., Salat D.H. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov. Disord. 2006, 21:1317-1325.
44. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2003, 12:1555-1567.
45. Smith M.A., Brandt J., Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 2000, 403:544-549.
46. Stephens B., Mueller A.J., Shering A.F., Hood S.H., Taggart P., Arbuthnott G.W., Bell J.E., Kilford L., Kingsbury A.E., Daniel S.E., Ingham C.A. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005, 132:741-754.
47. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A., Durr A., Craufurd D., Kennard C., Hicks S.L., Fox N.C., Scahill R.I., Borowsky B., Tobin A.J., Rosas H.D., Johnson H., Reilmann R., Landwehrmeyer B., Stout J.C. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8:791-801.
48. Tabrizi S.J., Scahill R.I., Durr A., Roos R.A., Leavitt B.R., Jones R., Landwehrmeyer G.B., Fox N.C., Johnson H., Hicks S.L., Kennard C., Craufurd D., Frost C., Langbehn D.R., Reilmann R., Stout J.C. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011, 10:31-42.
49. Tang T.S., Chen X., Liu J., Bezprozvanny I. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J. Neurosci. 2007, 27:7899-7910.
50. Thomas E.A., Coppola G., Tang B., Kuhn A., Kim S., Geschwind D.H., Brown T.B., Luthi-Carter R., Ehrlich M.E. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum. Mol. Genet. 2011, 20:1049-1060.
51. van Oostrom J.C., Maguire R.P., Verschuuren-Bemelmans C.C., Veenma-van der Duin L., Pruim J., Roos R.A., Leenders K.L. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 2005, 65:941-943.